Please login to the form below

Not currently logged in

Pfizer drives oncology R&D growth

Pfizer is to run seven new clinical studies into liver, renal cell carcinoma, lung and prostate cancers
Pfizer is to run seven new clinical studies into liver, renal cell carcinoma, lung and prostate cancers.

These studies are part of Pfizer's growing oncology research and development (R&D) programme, which has increased by 400 per cent since 2003. Dedicating just under a quarter of its overall R&D budget to oncology, the company currently has 22 compounds in 232 clinical studies.

"We are seeing our sustained efforts in oncology mature as our development programmes continue to advance into late-stage clinical trials," said Dr Charles Baum, vice-president of Pfizer Global Research and Development.

In 2008 alone, Pfizer has presented 299 new agents at the American Society of Clinical Oncology (ASCO) meeting. The company has also started two phase III studies and expects to start the remaining five by the end of the year.

A dedicated business unit, focused on oncology within Pfizer's worldwide pharmaceutical group, was established in March 2008. The unit will accelerate the launches of new oncology agents and focus research efforts on cancers common in Asia such as those of the liver, oesophagus and nasopharynx.

4th June 2008


Featured jobs

Subscribe to our email news alerts


Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...